Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy

Tünde Szatmári, Katalin Lumniczky, Szilvia Désaknai, Stéphane Trajcevski, Egon J. Hídvégi, Hirofumi Hamada, G. Sáfrány

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Mouse glioma 261 (Gl261) cells are used frequently in experimental glioblastoma therapy; however, no detailed description of the Gl261 tumor model is available. Here we present that Gl261 cells carry point mutations in the K-ras and p53 genes. Basal major histocompatibility complex (MHC)I, but not MHCII, expression was detected in Gl261 cells. The introduction of interferon-γ-encoding genes increased expression of both MHCI and MHCII. A low amount of B7-1 and B7-2 RNA was detected in wild-type cells, but cytokine production did not change expression levels. Gl261 cells were transduced efficiently by adenoviral vectors; the infectivity of retroviral vectors was limited. Low numbers of transplanted Gl261 cells formed both subcutaneous and intracranial tumors in C57BL/6 mice. The cells were moderately immunogenic: Prevaccination of mice with irradiated tumor cells 7 days before intracranial tumor challenge prevented tumor formation in approximately 90% of mice. When vaccination was carried out on the day or 3 days after tumor challenge, no surviving animals could be found. In vitro-growing cells were radiosensitive: Less than 2 Gy was required to achieve 50% cell mortality. Local tumor irradiation with 4 Gy X-rays in brain tumor-bearing mice slowed down tumor progression, but none of the mice were cured off the tumor. In conclusion, the Gl261 brain tumor model might be efficiently used to study the antitumor effects of various therapeutic modalities, but the moderate immunogenicity of the cells should be considered.

Original languageEnglish
Pages (from-to)546-553
Number of pages8
JournalCancer Science
Volume97
Issue number6
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Investigational Therapies
Glioblastoma
Glioma
Neoplasms
Brain Neoplasms
ras Genes
p53 Genes
Therapeutic Uses
Major Histocompatibility Complex
Inbred C57BL Mouse
Point Mutation
Interferons
Vaccination
X-Rays
RNA
Cytokines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. / Szatmári, Tünde; Lumniczky, Katalin; Désaknai, Szilvia; Trajcevski, Stéphane; Hídvégi, Egon J.; Hamada, Hirofumi; Sáfrány, G.

In: Cancer Science, Vol. 97, No. 6, 06.2006, p. 546-553.

Research output: Contribution to journalArticle

Szatmári, T, Lumniczky, K, Désaknai, S, Trajcevski, S, Hídvégi, EJ, Hamada, H & Sáfrány, G 2006, 'Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy', Cancer Science, vol. 97, no. 6, pp. 546-553. https://doi.org/10.1111/j.1349-7006.2006.00208.x
Szatmári T, Lumniczky K, Désaknai S, Trajcevski S, Hídvégi EJ, Hamada H et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Science. 2006 Jun;97(6):546-553. https://doi.org/10.1111/j.1349-7006.2006.00208.x
Szatmári, Tünde ; Lumniczky, Katalin ; Désaknai, Szilvia ; Trajcevski, Stéphane ; Hídvégi, Egon J. ; Hamada, Hirofumi ; Sáfrány, G. / Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. In: Cancer Science. 2006 ; Vol. 97, No. 6. pp. 546-553.
@article{b6b8504310f447dcb2d2110082c0b10f,
title = "Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy",
abstract = "Mouse glioma 261 (Gl261) cells are used frequently in experimental glioblastoma therapy; however, no detailed description of the Gl261 tumor model is available. Here we present that Gl261 cells carry point mutations in the K-ras and p53 genes. Basal major histocompatibility complex (MHC)I, but not MHCII, expression was detected in Gl261 cells. The introduction of interferon-γ-encoding genes increased expression of both MHCI and MHCII. A low amount of B7-1 and B7-2 RNA was detected in wild-type cells, but cytokine production did not change expression levels. Gl261 cells were transduced efficiently by adenoviral vectors; the infectivity of retroviral vectors was limited. Low numbers of transplanted Gl261 cells formed both subcutaneous and intracranial tumors in C57BL/6 mice. The cells were moderately immunogenic: Prevaccination of mice with irradiated tumor cells 7 days before intracranial tumor challenge prevented tumor formation in approximately 90{\%} of mice. When vaccination was carried out on the day or 3 days after tumor challenge, no surviving animals could be found. In vitro-growing cells were radiosensitive: Less than 2 Gy was required to achieve 50{\%} cell mortality. Local tumor irradiation with 4 Gy X-rays in brain tumor-bearing mice slowed down tumor progression, but none of the mice were cured off the tumor. In conclusion, the Gl261 brain tumor model might be efficiently used to study the antitumor effects of various therapeutic modalities, but the moderate immunogenicity of the cells should be considered.",
author = "T{\"u}nde Szatm{\'a}ri and Katalin Lumniczky and Szilvia D{\'e}saknai and St{\'e}phane Trajcevski and H{\'i}dv{\'e}gi, {Egon J.} and Hirofumi Hamada and G. S{\'a}fr{\'a}ny",
year = "2006",
month = "6",
doi = "10.1111/j.1349-7006.2006.00208.x",
language = "English",
volume = "97",
pages = "546--553",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy

AU - Szatmári, Tünde

AU - Lumniczky, Katalin

AU - Désaknai, Szilvia

AU - Trajcevski, Stéphane

AU - Hídvégi, Egon J.

AU - Hamada, Hirofumi

AU - Sáfrány, G.

PY - 2006/6

Y1 - 2006/6

N2 - Mouse glioma 261 (Gl261) cells are used frequently in experimental glioblastoma therapy; however, no detailed description of the Gl261 tumor model is available. Here we present that Gl261 cells carry point mutations in the K-ras and p53 genes. Basal major histocompatibility complex (MHC)I, but not MHCII, expression was detected in Gl261 cells. The introduction of interferon-γ-encoding genes increased expression of both MHCI and MHCII. A low amount of B7-1 and B7-2 RNA was detected in wild-type cells, but cytokine production did not change expression levels. Gl261 cells were transduced efficiently by adenoviral vectors; the infectivity of retroviral vectors was limited. Low numbers of transplanted Gl261 cells formed both subcutaneous and intracranial tumors in C57BL/6 mice. The cells were moderately immunogenic: Prevaccination of mice with irradiated tumor cells 7 days before intracranial tumor challenge prevented tumor formation in approximately 90% of mice. When vaccination was carried out on the day or 3 days after tumor challenge, no surviving animals could be found. In vitro-growing cells were radiosensitive: Less than 2 Gy was required to achieve 50% cell mortality. Local tumor irradiation with 4 Gy X-rays in brain tumor-bearing mice slowed down tumor progression, but none of the mice were cured off the tumor. In conclusion, the Gl261 brain tumor model might be efficiently used to study the antitumor effects of various therapeutic modalities, but the moderate immunogenicity of the cells should be considered.

AB - Mouse glioma 261 (Gl261) cells are used frequently in experimental glioblastoma therapy; however, no detailed description of the Gl261 tumor model is available. Here we present that Gl261 cells carry point mutations in the K-ras and p53 genes. Basal major histocompatibility complex (MHC)I, but not MHCII, expression was detected in Gl261 cells. The introduction of interferon-γ-encoding genes increased expression of both MHCI and MHCII. A low amount of B7-1 and B7-2 RNA was detected in wild-type cells, but cytokine production did not change expression levels. Gl261 cells were transduced efficiently by adenoviral vectors; the infectivity of retroviral vectors was limited. Low numbers of transplanted Gl261 cells formed both subcutaneous and intracranial tumors in C57BL/6 mice. The cells were moderately immunogenic: Prevaccination of mice with irradiated tumor cells 7 days before intracranial tumor challenge prevented tumor formation in approximately 90% of mice. When vaccination was carried out on the day or 3 days after tumor challenge, no surviving animals could be found. In vitro-growing cells were radiosensitive: Less than 2 Gy was required to achieve 50% cell mortality. Local tumor irradiation with 4 Gy X-rays in brain tumor-bearing mice slowed down tumor progression, but none of the mice were cured off the tumor. In conclusion, the Gl261 brain tumor model might be efficiently used to study the antitumor effects of various therapeutic modalities, but the moderate immunogenicity of the cells should be considered.

UR - http://www.scopus.com/inward/record.url?scp=33744548728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744548728&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2006.00208.x

DO - 10.1111/j.1349-7006.2006.00208.x

M3 - Article

VL - 97

SP - 546

EP - 553

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 6

ER -